We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01396070
First Posted: July 18, 2011
Last Update Posted: April 5, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Seattle Genetics, Inc.
Information provided by (Responsible Party):
Youn Kim, Stanford University
July 14, 2011
July 18, 2011
December 28, 2016
April 5, 2017
April 5, 2017
May 2011
April 2015   (Final data collection date for primary outcome measure)
Overall Response Rate (ORR) [ Time Frame: 2 years ]
Overall response rate of brentuximab vedotin in this study population.
Objective clinical response rate assessed by the standard response criteria used in MF (Mycosis fungoides) and SS (Sezary syndromel) [ Time Frame: 4 weeks ]
Complete list of historical versions of study NCT01396070 on ClinicalTrials.gov Archive Site
  • Overall Stable Disease Rate [ Time Frame: 2 years ]

    Overall Stable Disease Rate (SD) in this study population.

    3 subjects were not evaluable.

  • Overall Partial Response Rate [ Time Frame: 2 years ]

    Overall Partial Response Rate (PR) in this study population.

    3 subjects were not evaluable.

  • Overall Non-Evaluable Response [ Time Frame: 4 weeks ]

    Overall Non-Evaluable Response of full patient population

    3 subjects were not evaluable.
Not Provided
Not Provided
Not Provided
 
Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level
Exploratory Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level
The purpose of this study is to learn the effects of brentuximab vedotin (SGN-35), an investigational medication, on patients with cutaneous T cell lymphoma (CTCL), specifically mycosis fungoides (MF) and Sezary syndrome (SS). Despite a wide range of therapeutic options, the treatments are associated with short response duration, thus this condition is largely incurable. This investigational drug may offer less toxicity than standard treatments and have better tumor specific targeting.

This phase 2 exploratory study will evaluate the clinical response of brentuximab vedotin in MF and SS, where tumor cells express variable levels of CD30 target molecule.

The primary objective is to explore the biologic activity of brentuximab vedotin in patients with MF and SS, the most common types of cutaneous T-cell lymphoma (CTCL), where expression of CD30 is variable. Brentuximab vedotin has significant biologic activity in Hodgkin's disease (HD) where only a small numbers of CD30 positive tumor cells are present, as well as in lymphomas with large numbers of CD30-expressing tumor cells such as systemic anaplastic large cell lymphoma (sALCL). The subject grouping by CD30 expression levels (low, intermediate, high) is for accrual purposes only, to ensure that a wide range of CD30 expression is studied.
Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Non-Hodgkin Lymphoma (NHL)
  • Cutaneous Lymphoma
  • Cutaneous T-cell Lymphoma (CTCL)
  • Mycosis Fungoides
  • Sezary Syndrome
Drug: Brentuximab vedotin

1.8 mg/kg by IV every 3 weeks for a maximum of 16 doses (8 cycles).

Brentuximab vedotin is an antibody conjugate, consisting of the chimeric IgG1 anti-CD30 antibody cAC10; the microtubule disrupting agent monomethyl auristatin E (MMAE); a protease-cleavable linker that covalently attaches MMAE to cAC10.

Other Names:
  • Adcetris
  • SGN-35
Experimental: Brentuximab vedotin
Novel antibody-drug conjugate, 1.8 mg/kg intravenously every 3 weeks
Intervention: Drug: Brentuximab vedotin
Kim YH, Tavallaee M, Sundram U, Salva KA, Wood GS, Li S, Rozati S, Nagpal S, Krathen M, Reddy S, Hoppe RT, Nguyen-Lin A, Weng WK, Armstrong R, Pulitzer M, Advani RH, Horwitz SM. Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. J Clin Oncol. 2015 Nov 10;33(32):3750-8. doi: 10.1200/JCO.2014.60.3969. Epub 2015 Jul 20.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
36
May 2016
April 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Biopsy-proven MF/SS, stage IB-IVB, and failed one standard systemic therapy. Skin biopsy must be within 3 months of beginning study medication

  • At least the following wash-out from prior treatments:

    • ≥ 3 weeks for local radiation therapy, systemic cytotoxic anticancer therapy, treatment with other anti-cancer investigational agents (including monoclonal antibody)
    • > 3 weeks for retinoids, interferons, vorinostat, romidepsin, denileukin diftitox and phototherapy
    • > 2 wks for topical therapy (including topical steroid, retinoid, nitrogen mustard, or imiquimod)
  • At least 18 years of age
  • ECOG performance status of ≤ 2
  • Must be able to commit to study schedule
  • Absolute neutrophil count (ANC) ≥ 1000/uL
  • Platelets ≥ 50,000/uL
  • Bilirubin ≤ 2X upper limit of normal (ULN) (EXCEPTION: Gilbert's disease ≤ 3X ULN)
  • Serum creatinine ≤ 2X ULN
  • Alanine aminotransferase (ALT) ≤ 3X ULN
  • Aspartate aminotransferase (AST) ≤ 3X ULN
  • Negative serum beta-HCG pregnancy test result within 7 days of first treatment, if a woman of childbearing potential
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Mycosis fungoides (MF) with limited disease (stage IA) or central nervous system (CNS) disease
  • Systemic or topical concomitant corticosteroid use for treatment of skin disease (EXCEPTION: Oral prednisone allowed at ≤ 10 mg/day)
  • Known Grade 3 or higher (per NCI CTCAE v4.0 criteria) active systemic or cutaneous viral, bacterial, or fungal infection
  • Known to be Hepatitis B or Hepatitis C antibody positive
  • HIV-positive with have a measurable viral load while on antiretroviral medication
  • Known hypersensitivity to recombinant proteins or any excipient contained in the drug formulation.
  • History of other malignancies during the past 3 years (EXCEPTIONS: non-melanoma skin cancer; curatively treated localized prostate cancer; curatively treated localized breast cancer; resected thyroid cancer; cervical intraepithelial neoplasia; or cervical carcinoma in situ on biopsy).
  • Pregnant
  • Breastfeeding
  • Congestive heart failure, Class III or IV, by New York Heart Association (NYHA) criteria.
  • Any serious underlying medical condition that would impair subject's ability to receive or tolerate the planned treatment.
  • Dementia or altered mental status that would preclude subject's understanding and rendering of informed consent.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01396070
IRB-21324
LYMNHL0089 ( Other Identifier: OnCore )
SU-06212011-7946 ( Other Identifier: Stanford University )
Yes
Not Provided
Plan to Share IPD: No
Youn Kim, Stanford University
Youn Kim
Seattle Genetics, Inc.
Principal Investigator: Youn H Kim Stanford University
Stanford University
February 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP